banners
Kickas Main Page | Rights and Responsibilities | Donate to Kickas
Kickas Links
·HOME
·Forums Main Index
·Register!
MEDICAL CENTRE
·Medicine Contract
·AS Patient Guidebook
·Pain Map
·Disease Modification
·Ask your doctor
·AS and RA Papers
·AS Acronyms
DIET CENTRE
·London AS Diet
·Molecular Mimicry
·AS Dietary Primer
·AS Food Guide
SUPPORT CENTRE
·In Memorium
·KickAS Stories
·KickAS Banners
·Donations
Forum Stats
12,630 Registered Members
28 Forums
43,330 Topics
515,622 Posts

Most users ever online: 1,568 @ 06/29/16 03:25 PM
Newest Members
yurayurayura, Foonda, Dea, Navdeep, dwarner
12630 Registered Users
KickAs Team
Administrator/owner:
John (Dragonslayer)
Administrator:
Melinda (mig)
WebAdmin:
Timo (Timo)
Administrator:
Brad (wolverinefan)

Moderators:
- Tim (Dotyisle)
- Chelsea (Kiwi)
- Megan (Megan)
- Wendy (WendyR)
- John (Cheerful)
- Chris (fyrfytr187)

QR Code
If you want to use this QR code (Quick Response code) just save the image and paste it where you want. You can even print it and use it that way. Coffee cups, T-Shirts etc would all be good for the QR code.
Topic Options
#509979 - 03/23/15 07:09 PM Conventional DMARDs in axial spondyloarthritis ?
MollyC1i Offline
Very_Addicted_to_AS_Kickin

Registered: 01/21/04
Posts: 9709
Loc: Brittany, France (since Nov 08...
http://ard.bmj.com/content/early/2015/03/20/annrheumdis-2014-206758.full

Conventional DMARDs in axial spondyloarthritis: wishful––rather than rational thinking!

Robert B M Landewé1,2
+ Author Affiliations

1Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands
2Atrium Medical Center, Heerlen, The Netherlands
Correspondence to
Robert B M Landewé, Amsterdam Rheumatology and Immunology Center, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands; landewe@rlandewe.nl
Received 3 March 2015
Accepted 8 March 2015
Published Online First 20 March 2015

Conventional synthetic DMARD (csDMARD) therapy in patients with axial spondyloarthritis (SpA) is a matter of continuous debate. Part of this discussion is a dispute about methotrexate (MTX) comedication in patients with axial SpA treated with tumour necrosis factor inhibitors biologicals (TNFi). The dispute seems to be based on perceptions rather than scientific evidence and may have been fuelled by one of the European League Against Rheumatism task force on the management of rheumatoid arthritis (RA) recommendations. This recommendation states that in RA, TNFi-biologicals should be used in combination with MTX,1 which finds its justification in the results of multiple randomised clinical trials and careful posthoc analyses thereof. (more...)

(-----------)

"Taken together, Lie's study is an example of an observational study in which residual confounding seems a far too likely explanation for the association between TNFi-retention and csDMARD comedication to justify implementation in clinical practice. However, absence of evidence for a particular hypothesis is not the same as evidence for the absence of such a hypothesis! The best experiment to test the hypothesis that csDMARDs in axial SpA improve TNFi-retention is the well-powered RCT that randomises patients with axial SpA to either monotherapy with a biological or to combination therapy of a biological plus a csDMARD, follow them blindly for some time and compare clinical efficacy, safety and drug-retention in both arms. Such a trial is feasible, but costly, hard to fund and unfortunately not in the interest of pharmaceutical industries. This may explain why this trial likely will not be performed in near future. That is truly a pity, since for the benefit of our patients and the affordability of our healthcare systems we urgently need unequivocal answers to simple but extremely relevant clinical questions."

Footnotes
Competing interests The author is the current president of ASAS.

cat

Full article available - free edition
_________________________
MollyC1i - Riding OutAS

Top
#510002 - 03/24/15 03:00 PM Re: Conventional DMARDs in axial spondyloarthritis ? [Re: MollyC1i]
Eyeblog Offline
Member

Registered: 12/22/13
Posts: 39
Loc: North America
Hey Molly,

Thanks for posting this. At a recent appointment, the rheumatologist brought up switching from celebrex to MTX as a middle of the road choice before I start Humira (also because of Humira's cost). I have more eye, energy complaints than spinal damage.

She said that she has fewer patients who suffer problems from MTX than with Celebrex, but all the studies I see on it are pretty dated. Perhaps as mentioned above, "it's not in the interests of pharmaceutical industries".

Jeff
_________________________
My blog on iritis and uveitis: http://eyeblog.livejournal.com

Top
#510004 - 03/24/15 07:07 PM Re: Conventional DMARDs in axial spondyloarthritis ? [Re: Eyeblog]
snowshoe Offline
Platinum_AS_Kicker

Registered: 09/10/01
Posts: 1658
Loc: Lost
If you're in USA, many insurers require "step therapy" to determine whether you are resposive to lower cost meds before approving the expensive ones. NSAIDs and MTX are usually the first steps so perhaps that's what your Dr is doing. Not sure if that's required in Canada. The above quoted article is only relevant to the protocol of using TNFs with MTX. Best wishes
_________________________

This bunny Kicks AS !

Top
#510040 - 03/26/15 10:19 AM Re: Conventional DMARDs in axial spondyloarthritis ? [Re: Eyeblog]
MollyC1i Offline
Very_Addicted_to_AS_Kickin

Registered: 01/21/04
Posts: 9709
Loc: Brittany, France (since Nov 08...
Hi Jeff - you might find this useful - I had to smile at the final paragraph...!

UK Health Assessment Study: Older Drug Combos Equal TNF Drugs for RA

News | March 23, 2015 | Rheumatoid Arthritis, Musculoskeletal Citations
By Norman Bauman
Scott DL, Ibrahim F, Farewell F, et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h1046


Miossec P. Editorials: Drug treatments for rheumatoid arthritis: looking backwards to move forwards. BMJ 2015; 350 (13 March 2015) doi: http://dx.doi.org/10.1136/bmj.h1192

A UK study has found that that the older drugs are non-inferior to TNF inhibitors when methotrexate gave inadequate control of rheumatoid arthritis (RA).

Other randomized, controlled trials have concluded that the addition of sulfasalazine and hydroxychloroquine is non-inferior to the addition of tumor necrosis factor (TNF) inhibitors such as etanercept, although some rheumatologists say that those studies don’t square with their personal experience. (See MTX Fails in RA. What Next? Reviewers Respond.)

The TNF inhibitors Against Combination Intensive Therapy (TACIT) study was funded by the UK National Institute for Health Research Health Technology Assessment.

In the TACIT study, 205 patients who were eligible for treatment with TNF inhibitors under current English guidance were randomized to either a TNF inhibitor first strategy or a combined disease modifying drug first strategy. For non-responders, additional drugs, including TNF inhibitors, were added after six months.

The TNF inhibitors were adalimumab, etanercept, and infliximab, following local practice. The most common TNF inhibitor was adalimumab and the most common drug combination was methotrexate and leflunomide.

The primary outcome was reduction in disability at 12 months, measured by a patient-recorded health assessment questionnaire (range 0-3), with a 0.22 non-inferiority margin. Baseline scores were 1.9 (TNF inhibitor first group) and 1.8 (combined drug group). The change in scores over 12 months was -0.30 (TNF inhibitor first group) and -0.45 (combined drug group). The mean difference was -0.14, which was below the prespecified non-inferiority margin.

The initial reductions were greater in the TNF inhibitor first group, which indicates the rapid onset of TNF inhibitors, but that difference disappeared by 12 months.

The editorial says that we should not call both treatments equally good; we should call them equally bad. Current treatment regimens start too late. If we were to follow the model of cancer treatments, we would combine drugs at the start of treatment and not wait for traditional monotherapies to fail.

---------------------- ##

alien (or mebbe one just sighs...!)
_________________________
MollyC1i - Riding OutAS

Top
#510053 - 03/27/15 12:55 PM Re: Conventional DMARDs in axial spondyloarthritis ? [Re: MollyC1i]
Eyeblog Offline
Member

Registered: 12/22/13
Posts: 39
Loc: North America
Hey Molly--yeah, both bad, both laughing and sighing. Thanks for all your articles you post. Very helpful when I don't have time for the long research sessions. wink

Snowshoe--it's kind of the same in Canada. Unless I pay or have a group drug plan (through work), I won't be able to get Humira.

I took from my rheumatologist's comments that MTX, when it works, either in conjunction or otherwise can be just as safe and efficient as newer drugs. In Canada, however, they've had shortages of MTX in the past because it's not profitable to make and there's less research being done on it due to the focus on newer biologics.
_________________________
My blog on iritis and uveitis: http://eyeblog.livejournal.com

Top
#511382 - 06/14/15 09:08 PM Re: Conventional DMARDs in axial spondyloarthritis ? [Re: MollyC1i]
drizzit Offline
Silver_AS_Kicker

Registered: 02/25/06
Posts: 1483
Loc: Montana
Originally Posted By MollyC1i
Hi Jeff - you might find this useful - I had to smile at the final paragraph...!

UK Health Assessment Study: Older Drug Combos Equal TNF Drugs for RA

News | March 23, 2015 | Rheumatoid Arthritis, Musculoskeletal Citations
By Norman Bauman
Scott DL, Ibrahim F, Farewell F, et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h1046


Miossec P. Editorials: Drug treatments for rheumatoid arthritis: looking backwards to move forwards. BMJ 2015; 350 (13 March 2015) doi: http://dx.doi.org/10.1136/bmj.h1192

A UK study has found that that the older drugs are non-inferior to TNF inhibitors when methotrexate gave inadequate control of rheumatoid arthritis (RA).

Other randomized, controlled trials have concluded that the addition of sulfasalazine and hydroxychloroquine is non-inferior to the addition of tumor necrosis factor (TNF) inhibitors such as etanercept, although some rheumatologists say that those studies don�t square with their personal experience. (See MTX Fails in RA. What Next? Reviewers Respond.)

The TNF inhibitors Against Combination Intensive Therapy (TACIT) study was funded by the UK National Institute for Health Research Health Technology Assessment.

In the TACIT study, 205 patients who were eligible for treatment with TNF inhibitors under current English guidance were randomized to either a TNF inhibitor first strategy or a combined disease modifying drug first strategy. For non-responders, additional drugs, including TNF inhibitors, were added after six months.

The TNF inhibitors were adalimumab, etanercept, and infliximab, following local practice. The most common TNF inhibitor was adalimumab and the most common drug combination was methotrexate and leflunomide.

The primary outcome was reduction in disability at 12 months, measured by a patient-recorded health assessment questionnaire (range 0-3), with a 0.22 non-inferiority margin. Baseline scores were 1.9 (TNF inhibitor first group) and 1.8 (combined drug group). The change in scores over 12 months was -0.30 (TNF inhibitor first group) and -0.45 (combined drug group). The mean difference was -0.14, which was below the prespecified non-inferiority margin.

The initial reductions were greater in the TNF inhibitor first group, which indicates the rapid onset of TNF inhibitors, but that difference disappeared by 12 months.

The editorial says that we should not call both treatments equally good; we should call them equally bad. Current treatment regimens start too late. If we were to follow the model of cancer treatments, we would combine drugs at the start of treatment and not wait for traditional monotherapies to fail.

---------------------- ##

alien (or mebbe one just sighs...!)


Remember that RA and AS are not the same. This is about RA and not AS. TNF drugs work better in AS then they do in RA and the dmards really don't work at all in AS for the most part


Edited by drizzit (06/14/15 09:09 PM)
_________________________
No families take so little medicine as those of doctors, except those of apothecaries.

Oliver Wendell Holmes

Top

Moderator:  Megan, WendyR 
Who's Online
0 registered (), 147 Guests and 2 Spiders online.
Key: Admin, Global Mod, Mod
Recent Posts
Has anyone here had C. diff?
by MikeGinnyMD
07/17/17 09:10 AM
No sugar , No starch, say what?
by Amiron
07/17/17 04:15 AM
Pain relief
by Josh300788
07/16/17 02:26 PM
Radon Therapy Czech Republic
by Luigi
07/16/17 07:04 AM
Not getting notifications...
by EricaK
07/12/17 03:46 PM
Multiple Sclerosis link to Prof Ebringer & opinion
by DragonSlayer
07/10/17 03:48 PM
Going to start Cosentyx next--6th biologic
by rumble
07/09/17 02:05 AM
(Views)Popular Topics
"FITNESS" TEAM! - All Physical Activity & Sports 33,629,586
hmmm 1,668,768
Has anyone had Pedicle subtraction Osteotomy ? 1,435,460
What to do about healthcare? Can it be fixed? 923,771
User names revisited 808,126
Medicinal Marijuana 718,289
A.S and beds, What do you find best? 710,230
OMG!!!! 665,444
No/Low Starch Diet Success Stories 492,276
THE STARCH CONTENT OF FOODS - THE LIST 410,881